Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing platforms for cell and gene therapies, has scheduled its fourth quarter and full year 2024 financial results announcement for March 13, 2025, after US market close.
The company will host an investor conference call and webcast on March 14, 2025, at 8:00 AM ET / 1:00 PM CET to discuss the financial results and provide business updates. Investors can access the call through domestic (+1-800-225-9448) or international (+1-203-518-9708) dial-in numbers using Conference ID: CLLS24.
Cellectis (NASDAQ: CLLS), un'azienda biotecnologica in fase clinica focalizzata su piattaforme di editing genetico per terapie cellulari e geniche, ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per il 13 marzo 2025, dopo la chiusura del mercato statunitense.
L'azienda ospiterà una conferenza telefonica per gli investitori e una webcast il 14 marzo 2025, alle 8:00 AM ET / 1:00 PM CET per discutere i risultati finanziari e fornire aggiornamenti aziendali. Gli investitori possono accedere alla chiamata tramite numeri di telefono nazionali (+1-800-225-9448) o internazionali (+1-203-518-9708) utilizzando l'ID Conferenza: CLLS24.
Cellectis (NASDAQ: CLLS), una empresa biotecnológica en etapa clínica centrada en plataformas de edición genética para terapias celulares y génicas, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 13 de marzo de 2025, después del cierre del mercado en EE. UU.
La empresa llevará a cabo una conferencia telefónica para inversores y una transmisión en vivo el 14 de marzo de 2025, a las 8:00 AM ET / 1:00 PM CET para discutir los resultados financieros y proporcionar actualizaciones comerciales. Los inversores pueden acceder a la llamada a través de números de marcado nacionales (+1-800-225-9448) o internacionales (+1-203-518-9708) utilizando el ID de Conferencia: CLLS24.
Cellectis (NASDAQ: CLLS), 세포 및 유전자 치료를 위한 유전자 편집 플랫폼에 집중하는 임상 단계의 생명공학 회사가 2024년 4분기 및 전체 연도 재무 결과 발표를 2025년 3월 13일에 미국 시장 마감 후에 예정했습니다.
회사는 2025년 3월 14일 오전 8:00 ET / 오후 1:00 CET에 재무 결과를 논의하고 사업 업데이트를 제공하기 위해 투자자 컨퍼런스 콜 및 웹캐스트를 개최합니다. 투자자들은 국내 전화번호 (+1-800-225-9448) 또는 국제 전화번호 (+1-203-518-9708)를 통해 컨퍼런스 ID: CLLS24를 사용하여 전화를 접속할 수 있습니다.
Cellectis (NASDAQ: CLLS), une entreprise de biotechnologie en phase clinique axée sur les plateformes d'édition génétique pour les thérapies cellulaires et géniques, a prévu l'annonce de ses résultats financiers pour le quatrième trimestre et l'année complète 2024 pour le 13 mars 2025, après la clôture du marché américain.
L'entreprise organisera une conférence téléphonique pour les investisseurs et un webinaire le 14 mars 2025 à 8h00 ET / 13h00 CET pour discuter des résultats financiers et fournir des mises à jour sur l'activité. Les investisseurs peuvent accéder à l'appel via des numéros de téléphone nationaux (+1-800-225-9448) ou internationaux (+1-203-518-9708) en utilisant l'ID de conférence : CLLS24.
Cellectis (NASDAQ: CLLS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Gen-Editing-Plattformen für Zell- und Gentherapien konzentriert, hat die Bekanntgabe seiner finanziellen Ergebnisse für das 4. Quartal und das gesamte Jahr 2024 für den 13. März 2025 nach Börsenschluss in den USA angesetzt.
Das Unternehmen wird am 14. März 2025 um 8:00 Uhr ET / 13:00 Uhr CET eine Telefonkonferenz und ein Webcast für Investoren veranstalten, um die finanziellen Ergebnisse zu besprechen und Unternehmensupdates bereitzustellen. Investoren können über nationale (+1-800-225-9448) oder internationale (+1-203-518-9708) Telefonnummern mit der Konferenz-ID: CLLS24 auf die Konferenz zugreifen.
- None.
- None.
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2024 ending December 31, 2024 on Thursday, March 13, 2025 after the close of the US market.
The publication will be followed by an investor conference call and webcast on Friday, March 14, 2025, at 8:00 AM ET / 1:00 PM CET. The call will include the Company’s fourth quarter and full year 2024 results and an update on business activities. Details for the call are as follows:
Dial in information:
Domestic: +1-800-225-9448
International: +1-203-518-9708
Conference ID: CLLS24
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1706599&tp_key=4524940f8f
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.
Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.
TALEN® is a registered trademark owned by Cellectis.
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachment
FAQ
When will Cellectis (CLLS) release its Q4 and full year 2024 earnings?
What time is Cellectis (CLLS) Q4 2024 earnings call?
How can investors join Cellectis (CLLS) Q4 2024 earnings call?
What period will Cellectis (CLLS) financial results cover?
